The information contained in each press release and article is accurate only as of the date each press release and article was originally issued. According to present data Compass Pathways Plc - ADR's CMPS shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). The high price target for CMPS is $88.00 and the low price target for CMPS is $50.00. Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act. The average 1 … Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Reata Pharmaceuticals. Accelerating Growth: Unable to compare CMPS's earnings growth over the past year to its 5-year average as it is currently unprofitable. Earnings Trend: Insufficient data to determine if CMPS's year-on-year earnings growth rate was positive over the past 5 years. COMPASS Pathways PLC (CMPS) Stock Price: $34.95 USD -0.88 (-2.46%) Updated Jun 22, 2021 4:00 PM EDT - Market closed. September 2020. Psychedelic medicine company Compass Pathways plc (Nasdaq: CMPS) reported its financial results for the fourth quarter and year-end 2020 and gave an update on recent progress across its business. We are COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. $36.34. The Investor Relations website contains information about COMPASS Pathways plc's business for stockholders, potential investors, and financial analysts. Current Reports. Previous Next Compass Pathways (NASDAQ: CMPS)is currently pursuing COMP360 (synthetic psilocybin) for treatment-resistant depression (TRD). There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and Flexion Therapeutics (FLXN – Research Report) with bullish sentiments.COMPASS Pathways (CMPS) H.C. Wainwright analyst Patrick Trucchio initiated coverage with a Buy rating on COMPASS Pathways today and set a price target of $65.00. Eight research analysts have rated the stock with a buy rating. CMPS: COMPASS Pathways PLC Sponsored ADR - Full Company Report. The business On market share, the investment bank assumes initial COMP360 penetration of 0.1% at launch in 2026, which ramps to 2.25% by 2031. At least 3-5 years of experience in healthcare compliance or other risk management work experience in healthcare industry, health compliance programmes, or related fields. Certification in healthcare compliance is preferred. COMPASS Pathways’ fiscal year is from January 1 to December 31. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. Please note that any opinions, estimates or forecasts regarding COMPASS Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of COMPASS Pathways … COMPASS Pathways’ management team will host a conference call at 1.00pm UK (8.00am ET) on 13 May 2021. COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. Where is COMPASS Pathways based? COMPASS Pathways plc (NASDAQ:CMPS) posted its quarterly earnings results on Tuesday, March, 9th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.16. View COMPASS Pathways' earnings history. Get the hottest stocks to trade every day before the … The current price level -16.63% lower than the highest price of $61.69 marked by the stock while trading over the past 52-weeks, whereas it is 128.48% higher than the lowest price of $22.51 the company dropped to over past 52-weeks. COMPASS Pathways ADS (NASDAQ: CMPS): Q1 GAAP EPS of -$0.35. a biotech company that is developing psychedelic and evidence-based medicine and therapies for the challenges we have today in the realm of mental health. COMPASS Pathways plc (NASDAQ:CMPS) shares, rose in value on Friday, June 11, with the stock price up by 0.71% to the previous day’s close as strong demand from buyers drove the stock to $39.68. COMPASS Pathways ADS reports Q1 results. Filing by person (s) reporting owned … 0001628280-21-010978.xls. COMPASS Pathways plc [NASDAQ: CMPS] price surged by 11.86 percent to reach at $5.3. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a … COMPASS Pathways (CMPS) In a report released today, Sumant Kulkarni from Canaccord Genuity initiated coverage with a Buy rating on COMPASS Pathways and a price target of $80.00. Full Company Report for CMPS This page has not been authorized, sponsored, or otherwise approved … At a glance. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. Get the latest broker reports from Zacks Investment Research. COMPASS Pathways plc is followed by the analysts listed above. Wall Street analysts expect that COMPASS Pathways plc (NASDAQ:CMPS) will report earnings of ($0.33) per share for the current quarter, according to Zacks. May 13, 2021 7:28 AM ET COMPASS Pathways plc (CMPS) By: Pranav Ghumatkar, SA News Editor. It could happen, so consider a position in CMPS stock. Highlights include $146.6 million IPO, continued progress with phase IIb psilocybin therapy clinical trial, strengthened board and leadership team, and launch of Drug Discovery Center Highlights include... Amount of Analyst Coverage. The company reported total net losses of $13.2 million, $19.6 million and $24.8 million, respectively, for the fiscal […] The company said it plans to list its American depositary shares on the Nasdaq under the ticker “CMPS”. COMPASS Pathways corporate headquarters are in London, UK. COMPASS Pathways is not owned by hedge funds. When did COMPASS Pathways go public? May 24, 2021. COMPASS Pathways plc is headquartered in London, UK. Linda McGoldrick joins COMPASS board. 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COMPASS Pathways stock. View analyst ratings for COMPASS Pathways or view top-rated stocks. Data is currently not available. NasdaqGS:CMPS Earnings and Revenue Growth April 12th 2021. COMPASS Pathways is a business that is trying to treat a serious form of depression by using psilocybin, which is known for its psychoactive effects. COMPASS Pathways plc (CMPS) saw downtrend of -7.90% in the recent trading with $35.92 being its most recent. The company’s shares closed last Monday at $35.16. This positive analyst news continued last week when Compass Pathways received coverage from Cantor Fitzgerald, a top financial services firm.The report gave Compass Pathways an Overweight rating (stock expected to increase and perform above the industry average), with a price target of $71.00 – more than double the stock’s current price. 7 Wall Street analysts have issued ratings and price targets for COMPASS Pathways in the last 12 months. COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. We also have offices in New York, US. Linda is Chairman and CEO of Financial Health Associates International. Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. Zero analysts have provided estimates for COMPASS Pathways' earnings. a company we’ve profiled in the past, and which is currently developing a therapy that uses synthetic psilocybin, Add to Watchlist. The company report on February 11, 2021 that 264 Million Reasons Psychedelic Stocks Have More Room to Grow.. Get the hottest stocks to trade every day before the market opens 100% free. The press releases and articles contained in this section are provided for historical purposes only. COMPASS Pathways beats Reata Pharmaceuticals on 8 of the 11 factors compared between the two stocks. Shares of COMPASS Pathways plc (NASDAQ:CMPS) have received a consensus rating of "Buy" from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. We want to transform the patient experience in … Our data shows that ATAI Life … Their average twelve-month price target is $70.80, predicting that the stock has a possible upside of 98.32%. Nasdaq 100. COMPASS Pathways Plc American Depository Shares (CMPS) Nasdaq Listed. A Bachelor’s degree is required. When is COMPASS Pathways’ fiscal year? According to analysts' consensus price target of $70.80, COMPASS Pathways has a forecasted upside of 97.6% from its current price of $35.83. Healthcare compliance, SEC compliance, legal/paralegal, or related degree preferred. Market participants underestimate clinical trial probabilities of success in rNPV models based on average success probabilities in the psychiatric field. COMPASS Pathways plc (CMPS) saw downtrend of -10.56% in the recent trading with $51.43 being its most recent. The lowest EPS estimate is ($0.36) and the highest is ($0.30). Get the latest Full Company Report for COMPASS Pathways PLC Sponsored ADR from Zacks Investment Research SC 13D. We are COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations. COMPASS Pathways has only been the subject of 2 research reports in the past 90 days. The current price level -44.84% lower than the highest price of $61.69 marked by the stock while trading over the past 52-weeks, whereas it is 51.18% higher than the lowest price of $22.51 the company dropped to over past 52-weeks. Overall, Canaccord believes market potential reaches tens of billions of dollars annually, with Compass Pathways vying for unadjusted peak sales potential of $3.3 billion in the U.S., and $1.0 billion in Europe by 2031. Analysts bullish on Compass Pathways. >Analyst Target Prices. Past Earnings Growth Analysis. 0001628280-21-010978.pdf. The chart at the top shows a one-year chart for the symbol, with Earnings highlighted. 0001628280-21-010978.rtf. Discovery Center established. View HTML. COMPASS Pathways completed its IPO in September 2020. Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. COMPASS Pathways plc (CMPS) saw downtrend of -5.34% in the recent trading with $34.03 being its most recent. Summary. -0.23 (-0.63%) DATA AS OF Jun 18, 2021. Currently, the analyst consensus on COMPASS Pathways is a Strong Buy with an average price target of $65.00, implying an 82.2% upside from current levels. COMPASS Pathways has a consensus price target of $70.80, indicating a potential upside of 94.40%. CMPS: COMPASS Pathways PLC Sponsored ADR broker reports. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Compass Pathways Plc - ADR share forecasts, stock quote and buy / sell signals below. Our first programme is researching how psilocybin therapy could help people with treatment-resistant depression. August 2020. We are working with University of the Sciences (Philadelphia, USA) to develop new optimised psychedelic compounds targeting the 5-HT 2A receptor. The current price level -41.77% lower than the highest price of $61.69 marked by the stock while trading over the past 52-weeks, whereas it is 59.57% higher than the lowest price of $22.51 the company dropped to over past 52-weeks. This is the first of a number of investigator-initiated studies using COMP360 to report data, and was an exploratory … >Historical Ratings CMPS updated stock price target summary. COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The UK-based mental health company known for its psychedelic treatments, Compass Pathways has filed to go public this week. The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by …
Fallen Giant Clubs Fm20, Finger Tracking While Reading, Blue Goodwill Boutique, Davenport University Football, Clark County Wa Property Search, Quaid E Azam Mother Name, Do Propane Tanks Explode When Shot,